---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069783"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:05:54.927973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q1 2025 net income $112.9M; advances zorevunersen Phase 3 with Biogen

## Summary
- Net income $112.9M ($1.90 diluted EPS) in Q1 2025 vs net loss $26.4M ($0.57 per share) in Q1 2024.
- Revenue $158.5M, including $152.4M from Biogen license fee and $6.1M from Acadia partnership.
- Cash position $380.3M as of Mar 31, 2025; projected to fund operations beyond mid-2028.
- Phase 3 EMPEROR study of zorevunersen for Dravet syndrome cleared with FDA, EMA, PMDA; enrollment in Q2 2025.
- Biogen collaboration: $165M upfront, potential $385M milestones, tiered royalties; Stoke retains North America rights.

## SEC filing metadata
- accession: 0000950170-25-069783
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017025069783/0000950170-25-069783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017025069783/stok-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069783
- JSON: https://secwatch.observer/filing/0000950170-25-069783.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.